The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Ma, Junliang ^a   Liu, Lunxu ^a   Che, Guowei ^a   Yu, Nanbin ^a,b   Dai, Fuqiang ^a,c   You, Zongbing ^d  

^a SICHUAN UNIVERSITY   (China)

^b The Third People's Hospital of Zigong City   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; CELL DENSITY; CELLULAR DISTRIBUTION; COMPUTER ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; PROGNOSIS; RETROSPECTIVE STUDY; STROMA CELL; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; AGED; BIOSYNTHESIS; GENE EXPRESSION REGULATION; LUNG TUMOR; MACROPHAGE; METABOLISM; MIDDLE AGED; MORTALITY; TIME; TREATMENT OUTCOME;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA-DR ANTIGENS; HUMANS; LUNG NEOPLASMS; MACROPHAGES; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952937103     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-112     Document Type: Article

References (22)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111(6):1710-1717. 10.1378/chest.111.6.1710, 9187198.
2. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66(2):605-612. 10.1158/0008-5472.CAN-05-4005, 16423985.
3. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol 2007, 37(1):14-16. 10.1002/eji.200636910, 17183610.
4. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005, 23(35):8959-8967. 10.1200/JCO.2005.01.4910, 16219934.
5. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005, 23(4):344-346. 10.1016/j.immuni.2005.10.001, 16226499.
6. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Zembala M. Tumour-derived microvesicles modulate biological activity of human monocytes. Immunol Lett 2007, 113(2):76-82. 10.1016/j.imlet.2007.07.014, 17825925.
7. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23(11):549-555. 10.1016/S1471-4906(02)02302-5, 12401408.
8. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3(1):23-35. 10.1038/nri978, 12511873.
9. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 2009, 33(1):118-126. 10.1183/09031936.00065708, 19118225.
10. Yu N, Pu J, Pu Q, Che G, Zhang S, Liu L. Influence of Tumor Associated Macrophages Distribution on Prognosis of Non-small Cell Lung Cancer. Chin J Clin Thorac Cardiovasc Surg 2009, 16(1):44-47.
11. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992, 13(7):265-270. 10.1016/0167-5699(92)90008-U, 1388654.
12. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357(9255):539-545. 10.1016/S0140-6736(00)04046-0, 11229684.
13. Chen JJ, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, Lee YC, Yang PC. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003, 9(2):729-737.
14. Toomey D, Smyth G, Condron C, Kelly J, Byrne AM, Kay E, Conroy RM, Broe P, Bouchier-Hayes D. Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up. Int J Cancer 2003, 103(3):408-412. 10.1002/ijc.10836, 12471625.
15. Ohno S, Inagawa H, Soma G, Nagasue N. Role of tumor-associated macrophage in malignant tumors: should the location of the infiltrated macrophages be taken into account during evaluation?. Anticancer Res 2002, 22(6C):4269-4275.
16. Kim DW, Min HS, Lee KH, Kim YJ, Oh DY, Jeon YK, Lee SH, Im SA, Chung DH, Kim YT, et al. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer 2008, 98(6):1118-1124. 10.1038/sj.bjc.6604256, 2275476, 18283317.
17. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008, 113(6):1387-1395. 10.1002/cncr.23712, 18671239.
18. Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 2009, 55(3):301-312. 10.1111/j.1365-2559.2009.03379.x, 19723145.
19. Geissmann F, Dieu-Nosjean MC, Dezutter C, Valladeau J, Kayal S, Leborgne M, Brousse N, Saeland S, Davoust J. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med 2002, 196(4):417-430. 10.1084/jem.20020018, 2196053, 12186835.
20. Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoneda K, Imamura S, Schmitt D, Banchereau J. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med 1996, 184(2):695-706. 10.1084/jem.184.2.695, 2192705, 8760823.
21. Nakamura H, Saji H, Aute I, Kawasaki N, Hosaka M, Ogata A, Saijo T, Kato H. Peripheral leukocytes with HLA-DR+/CD8- phenotype are associated with prognosis in patients with lung cancer. Anticancer Res 2003, 23(5b):4149-4152.
22. Maniecki MB, Moller HJ, Moestrup SK, Moller BK. CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology 2006, 211(6-8):407-417. 10.1016/j.imbio.2006.05.019, 16920480.